drugset / Trial / NCT00150995
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.
Timeline
- Start
- 2001-05
- Primary completion
- 2003-10
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tetrathiomolybdate | Unknown | 40 mg | — |
| Subject | Tetrathiomolybdate | Unknown | 60 mg | — |